- 41% of patients had at least one ABRAXANE dose reduction
- 71% of patients had at least one ABRAXANE dose withheld or delayed
DOSING THAT DELIVERS
A well-established regimen for your patients

- Starting dose of 125 mg/m2
- Administer ABRAXANE, followed by gemcitabine 1000 mg/m2, on Days 1, 8, and 15 of each 28-day cycle
- 30- to 40-minute IV infusion
NOTE: DO NOT SUBSTITUTE FOR OR WITH OTHER PACLITAXEL FORMULATIONS. ABRAXANE has different dosage and administration instructions from other paclitaxel products.
A WELL-DEFINED DOSE MODIFICATION SCHEDULE


- Use in Patients With Hepatic Impairment
STARTING DOSE FOR PATIENTS
WITH HEPATIC IMPAIRMENT- Patients with bilirubin levels above the ULN were excluded from the MPACT study (central lab ULN in the MPACT study was 1.5 mg/dL)
- AST=aspartate aminotransferase; SGOT=serum glutamic-oxaloacetic transaminase.
- MPACT Modifications Timing
UNDERSTANDING TIMING OF DOSE MODIFICATIONS
DURING ABRAXANE + GEMCITABINE THERAPY9 UNDERSTANDING TIMING OF DOSE MODIFICATIONS DURING ABRAXANE + GEMCITABINE
THERAPY9- a First 2 cycles.
- % of ABRAXANE Patients Receiving 125 mg/m2 at the Start of Each Treatment Cycle
THE APPROVED STARTING DOSE OF 125 mg/m2
Percentage of ABRAXANE patients receiving 125 mg/m2 at the start of each treatment cycle9,a Percentage of ABRAXANE patients receiving 125 mg/m2 at the start of each treatment cycle9,a- Median duration of treatment: 3.9 months (range 0.1 to 21.9 months)3
- aWithin the MPACT study there were also dose modifications to the gemcitabine dose within the ABRAXANE + gemcitabine arm. Those modifications are not shown here. aWithin the MPACT study there were also dose modifications to the gemcitabine dose within the ABRAXANE + gemcitabine arm. Those modifications are not shown here.
- bCycle 1=8 weeks; subsequent cycles=4 weeks each.